{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:24:26Z","timestamp":1777436666180,"version":"3.51.4"},"reference-count":101,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2022,3,4]]},"DOI":"10.1080\/14656566.2021.2020249","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T14:39:00Z","timestamp":1640183940000},"page":"453-464","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["What\u2019s new on the front-line of gout pharmacotherapy?"],"prefix":"10.1080","volume":"23","author":[{"given":"Kurt E. G.","family":"Blake","sequence":"first","affiliation":[{"name":"Clinical Fellow, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan L.","family":"Saag","sequence":"additional","affiliation":[{"name":"Medical Student, University of Central Florida College of Medicine, Orlando, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth G","family":"Saag","sequence":"additional","affiliation":[{"name":"Director, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Al, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00346-9"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0441-1"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.04.008"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04868-9"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1532904"},{"key":"e_1_3_4_8_1","volume-title":"Lippincott\u2019s primary care rheumatology","author":"Boulware DW","year":"2012","unstructured":"Boulware DW, Heudebert GR. Lippincott\u2019s primary care rheumatology. Philadelphia PA: Wolters Kluwer Health\/Lippincott Williams & Wilkins; 2012."},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-54"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-016-1008-0"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0492-x"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0890-9"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.27421"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3951"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41614"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9896757"},{"issue":"5","key":"e_1_3_4_17_1","first-page":"679","article-title":"Drug-induced hyperuricaemia and gout","volume":"56","author":"Ben Salem C","year":"2016","unstructured":"Ben Salem C, Slim R, Fathallah N, et al. Drug-induced hyperuricaemia and gout. Rheumatology. 2016;56(5):679\u2013688. Accessed 6\/8\/2021.","journal-title":"Rheumatology"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036748"},{"issue":"13","key":"e_1_3_4_19_1","first-page":"215","article-title":"Treatment options for gout","volume":"114","author":"Engel B","year":"2017","unstructured":"Engel B, Just J, Bleckwenn M, et al. Treatment options for gout. Dtsch Arztebl Int. 2017;114(13):215\u2013222.","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16893-1"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.013"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27327"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab303"},{"key":"e_1_3_4_25_1","first-page":"171","volume-title":"Pharmacology and therapeutics of asthma and copd","author":"Adcock IM","year":"2017","unstructured":"Adcock IM, Mumby S. Glucocorticoids. In: Page CP, Barnes PJ, editors. Pharmacology and therapeutics of asthma and copd. Cham: Springer International Publishing; 2017. p. 171\u2013196."},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2070"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170137"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.09.006"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2012.09.009"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.02.003"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1179544119890853"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key402"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181018"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41699"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1167"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200908"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24402"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.4566"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215315"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22855"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32158-5"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10511"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1269745"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746080-00001"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.40.3.245"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7517.623"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290111"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0084-0"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.510"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21817"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex422"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328330a3b8"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1166"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.10.009"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13143"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094294"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.113"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34488"},{"issue":"8","key":"e_1_3_4_60_1","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth N","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33(8):1646\u20131650.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210872"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"e_1_3_4_64_1","unstructured":"FDA adds boxed warning for increased risk of death with gout medicine uloric (febuxostat). [cited 2021 July 15]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710895"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez552"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32234-0"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4377-2864-4.10012-0"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.052"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08488"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00854.2013"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10251"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2016.05.002"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20634"},{"issue":"5","key":"e_1_3_4_75_1","first-page":"651","article-title":"Benzbromarone withdrawn from the European market: another case of \u201cabsence of evidence is evidence of absence\u201d?","volume":"22","author":"Jansen TL","year":"2004","unstructured":"Jansen TL. Benzbromarone withdrawn from the European market: another case of \u201cabsence of evidence is evidence of absence\u201d? Clin Exp Rheumatol. 2004;22(5):651.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_76_1","volume-title":"Livertox: clinical and research information on drug-induced liver injury","author":"National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)","year":"2012","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (U.S.).Livertox: clinical and research information on drug-induced liver injury.Bethesda (MD):National Institute of Diabetes and Digestive and Kidney Diseases.2012.1 online resource (1 PDF file)."},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep33082"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39840"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209213"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40159"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1538003"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.09.009"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000584"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1210\/me.2008-0473"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-eular.2860"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1699-4"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39684"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-01851-6"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-01849-0"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab198"},{"key":"e_1_3_4_91_1","first-page":"suppl 10","article-title":"Ar882, a potent and selective uricosuric agent, significantly reduced serum urate in patients with gout in a phase 2a study [abstract]","volume":"72","author":"Yeh L-T","year":"2020","unstructured":"Yeh L-T, Polvent E, Shen Z, et al. Ar882, a potent and selective uricosuric agent, significantly reduced serum urate in patients with gout in a phase 2a study [abstract]. Arthritis Rheumatol. 2020;72:suppl 10. [cited 2021 August 1]. Available from: https:\/\/acrabstracts.org\/abstract\/ar882-a-potent-and-selective-uricosuric-agent-significantly-reduced-serum-urate-in-patients-with-gout-in-a-phase-2a-study\/","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"e_1_3_4_92_1","first-page":"1976","article-title":"Urc102, a potent and selective inhibitor of hurat1, reduced serum uric acid in healthy volunteers","volume":"58","author":"Lee HA","year":"2019","unstructured":"Lee HA, Yu KS, Park SI, et al. Urc102, a potent and selective inhibitor of hurat1, reduced serum uric acid in healthy volunteers. Rheumatology (Oxford). 2019;58(11):1976\u20131984.","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_3_4_93_1","unstructured":"ClinicalTrials.gov. The safety tolerability pharmacokinetics and pharmacodynamics of xnw3009 in healthy subjects (nct04040907). 2019. [cited 2021 August1]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04040907"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.23.9412"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1169"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4318"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111375"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4497"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1396-8"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-0151-9"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200460"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41731"},{"key":"e_1_3_4_103_1","unstructured":"ClinicalTrials.gov. Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple) (nct02598596). 2019. [cited 2021 August 1]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02598596?term=pegloticase\u00a7triple&rank=1"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2021.2020249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:40:48Z","timestamp":1732092048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2021.2020249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3,4]]}},"alternative-id":["10.1080\/14656566.2021.2020249"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2021.2020249","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-08-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}